Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants

(2021) Qianqian Li et al.   CELL

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

(2021) Daming Zhou et al.   CELL

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

(2021) Xiaoying Shen et al.   Cell Host & Microbe

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

(2021) Zhuoming Liu et al.   Cell Host & Microbe

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

(2021) Ester C Sabino et al.   LANCET

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

(2021) Rita E. Chen et al.   NATURE MEDICINE

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

(2021) Nicholas G. Davies et al.   SCIENCE

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

(2021) Wilfredo F. Garcia-Beltran et al.   CELL

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

(2021) Xianding Deng et al.   CELL

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

(2021) Xiaoying Shen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes

(2021) Lin Cheng et al.   Virology Journal

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

(2021) Mark S Graham et al.   Lancet Public Health

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

(2021) Yunlong Cao et al.   CELL RESEARCH

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

(2020) Tyler N. Starr et al.   CELL

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

(2020) Qianqian Li et al.   CELL

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

(2020) Yunlong Cao et al.   CELL

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

(2020) Bette Korber et al.   CELL

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

(2020) Dorothea Bestle et al.   Life Science Alliance

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

(2020) Jianhui Nie et al.   Nature Protocols

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

(2020) Shipo Wu et al.   Nature Communications

SARS-CoV-2 and the human-animal interface: outbreaks on mink farms

(2020) Marion Koopmans   LANCET INFECTIOUS DISEASES